# ABOS catalysts: Acumen Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/abos/catalysts

> Acumen Pharmaceuticals, Inc. (ABOS) has 1 upcoming catalyst. The next is the sabirnetug topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ABOS?

Acumen Pharmaceuticals, Inc. (ABOS) has 1 upcoming catalyst. The next is the sabirnetug topline data readout, early 2027. Press release filed with the SEC (EX-99): "Forward-looking statements include statements concerning Acumen's business, and Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, the potential for additional development to support a subcutaneous dosing option of sabirnetug, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology." [Calendar and source filings](https://sec-api.dev/companies/abos/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001576885-25-000102, https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112xexx991.htm (retrieved 2026-11-12). Last confirmed 2025-11-12. Cite: https://sec-api.dev/companies/abos/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Acumen Pharmaceuticals, Inc. |
| Ticker | ABOS (Nasdaq) |
| SEC CIK | 1576885 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/abos |

## Cash runway

Cash $78.6M as of 2026-09-30; quarterly burn $26.7M; about 8.8 months of runway at that rate (XBRL company facts, accession 0001628280-26-067276).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jul 2023 | [Sabirnetug topline data readout](https://sec-api.dev/pdufa/sabirnetug) | ABOS |  | completed, met | "In July 2023, the Company announced top-line results from its Phase 1 INTERCEPT-AD clinical trial of sabirnetug, which demonstrated that sabirnetug met the primary and secondary objectives of this clinical trial in 62 participants with early AD." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067276/abos-20260930.htm)) |
| May 2024 | [Sabirnetug trial start](https://sec-api.dev/pdufa/sabirnetug) | ABOS |  | completed | "We initiated our Phase 2 clinical trial, ALTITUDE-AD, in May 2024, completed enrollment in March 2025 and expect to announce top-line results in late 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm)) |
| November 12, 2024 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112xexx991.htm)) |
| Q1 2025 | [Sabirnetug topline data readout](https://sec-api.dev/pdufa/sabirnetug) | ABOS |  | scheduled | "•Expect to announce topline results of Phase 1 study to support subcutaneous administration of sabirnetug in the first quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688524000096/abos-20241112xexx991.htm)) |
| March 27, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327xexx991.htm)) |
| May 13, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000062/abos-20250513xexx991.htm)) |
| August 12, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/abos-20250812xexx991.htm)) |
| Nov 2025 | [Sabirnetug trial start](https://sec-api.dev/pdufa/sabirnetug) | ABOS | early Alzheimer's disease | completed | "•In November 2025, the Company dosed the first patient in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug (ACU193) in patients with early Alzheimer's disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326xexx991.htm)) |
| November 12, 2025 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112xexx991.htm)) |
| March 26, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326xexx991.htm)) |
| May 12, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026033868/abos-20260512xexx991.htm)) |
| August 12, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/abos-20260812xexx991.htm)) |
| late 2026 | [Acumen Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | scheduled | "As noted above, we expect to announce topline results of our Phase 2 clinical trial, ALTITUDE-AD, in late 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021413/abos-20251231.htm)) |
| October 26, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/abos-20261026xexx991.htm)) |
| October 29, 2026 | [Sabirnetug primary completion](https://sec-api.dev/pdufa/sabirnetug) | ABOS | Alzheimer Disease | completed | "NCT06335173 (A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Acumen Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06335173)) |
| Nov 2026 | [Sabirnetug topline data readout](https://sec-api.dev/pdufa/sabirnetug) | ABOS | early Alzheimer's disease, in late 2026 | scheduled | "Topline results expected in November 2026 Key Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/acumen_ncxcorporatexdeck.htm)) |
| Nov 2026 | [Acumen Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | scheduled | "•The Company expects to report topline results from ALTITUDE-AD in November 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026067129/abos-20261026xexx991.htm)) |
| early 2027 | [Sabirnetug topline data readout](https://sec-api.dev/pdufa/sabirnetug) | ABOS | Alzheimer's Disease utilizing EBD technology | scheduled | "Forward-looking statements include statements concerning Acumen's business, and Acumen's ability to achieve its strategic and financial goals, including its projected use of cash, cash equivalents and marketable securities and the expected sufficiency of its cash resources into early 2027, the therapeutic potential of Acumen's product candidate, sabirnetug (ACU193), including against other antibodies, the timing of anticipated topline results of ALTITUDE-AD, the potential for additional development to support a subcutaneous dosing option of sabirnetug, and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000157688525000102/abos-20251112xexx991.htm)) |

## Drugs

- [Sabirnetug](https://sec-api.dev/pdufa/sabirnetug): early alzheimer's disease, in late 2026, alzheimer's disease utilizing ebd technology, early ad, early alzheimer's disease, in november 2026, early ad, and today i'm pleased to announce, early ad, with topline results, Alzheimer Disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/abos/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ABOS catalysts: Acumen Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/abos/catalysts

```bibtex
@misc{secapidev_companies_abos_catalysts_20261116,
  title        = {ABOS catalysts: Acumen Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/abos/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_abos_catalysts_20261116","title":"ABOS catalysts: Acumen Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/abos/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
